Skip to main content
. Author manuscript; available in PMC: 2019 Mar 27.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2018 Jun 12;27(8):848–856. doi: 10.1002/pds.4565

FIGURE 5.

FIGURE 5

Number of patients receiving any implantable cardioverter defibrillator who received a model that accrued sufficient utilization 2 years post‐first implantation to detect safety differences for adverse event and complication rates of 3.9, 6.1, and 12.6 events per 100 person‐years and rate ratios of 1.05, 1.15, 1.25, 1.50, and 2.00 at significance level α=0.05